AVITA Medical Inc (RCEL)
8.75
+0.10
(+1.16%)
USD |
NASDAQ |
May 02, 16:00
8.75
0.00 (0.00%)
After-Hours: 16:09
AVITA Medical Research and Development Expense (Quarterly): 6.765M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.765M |
| September 30, 2023 | 4.394M |
| June 30, 2023 | 5.076M |
| March 31, 2023 | 4.586M |
| December 31, 2022 | 3.379M |
| September 30, 2022 | 3.799M |
| June 30, 2022 | 3.059M |
| March 31, 2022 | 3.62M |
| September 30, 2021 | 3.388M |
| Date | Value |
|---|---|
| June 30, 2021 | 3.974M |
| March 31, 2021 | 4.109M |
| December 31, 2020 | 3.361M |
| September 30, 2020 | 3.374M |
| June 30, 2020 | 2.538M |
| March 31, 2020 | 2.495M |
| December 31, 2019 | 2.312M |
| September 30, 2019 | 1.635M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.635M
Minimum
Sep 2019
6.765M
Maximum
Dec 2023
3.639M
Average
3.388M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 6.08M |
| Retractable Technologies Inc | 0.1617M |
| Xtant Medical Holdings Inc | 0.492M |
| Asensus Surgical Inc | 8.614M |
| Catheter Precision Inc | -0.011M |